- Home
- CSTL vs EVGO Comparison
CSTL vs EVGO Comparison
Compare CSTL & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- EVGO
- Stock Information
- Founded
- CSTL 2007
- EVGO 2010
- Country
- CSTL United States
- EVGO United States
- Employees
- CSTL N/A
- EVGO N/A
- Industry
- CSTL Medical Specialities
- EVGO Other Specialty Stores
- Sector
- CSTL Health Care
- EVGO Consumer Discretionary
- Exchange
- CSTL Nasdaq
- EVGO Nasdaq
- Market Cap
- CSTL 561.9M
- EVGO 462.9M
- IPO Year
- CSTL 2019
- EVGO N/A
- Fundamental
- Price
- CSTL $16.67
- EVGO $3.41
- Analyst Decision
- CSTL Strong Buy
- EVGO Buy
- Analyst Count
- CSTL 6
- EVGO 9
- Target Price
- CSTL $37.67
- EVGO $6.13
- AVG Volume (30 Days)
- CSTL 370.3K
- EVGO 3.7M
- Earning Date
- CSTL 08-04-2025
- EVGO 08-05-2025
- Dividend Yield
- CSTL N/A
- EVGO N/A
- EPS Growth
- CSTL N/A
- EVGO N/A
- EPS
- CSTL N/A
- EVGO N/A
- Revenue
- CSTL $347,083,000.00
- EVGO $276,954,000.00
- Revenue This Year
- CSTL N/A
- EVGO $40.85
- Revenue Next Year
- CSTL $1.36
- EVGO $32.70
- P/E Ratio
- CSTL N/A
- EVGO N/A
- Revenue Growth
- CSTL 38.43
- EVGO 45.15
- 52 Week Low
- CSTL $15.45
- EVGO $2.20
- 52 Week High
- CSTL $35.84
- EVGO $9.07
- Technical
- Relative Strength Index (RSI)
- CSTL 33.76
- EVGO 40.40
- Support Level
- CSTL $16.00
- EVGO $3.82
- Resistance Level
- CSTL $16.65
- EVGO $3.87
- Average True Range (ATR)
- CSTL 0.76
- EVGO 0.22
- MACD
- CSTL -0.30
- EVGO -0.01
- Stochastic Oscillator
- CSTL 5.40
- EVGO 9.20
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.